0000899243-22-032236.txt : 20220929 0000899243-22-032236.hdr.sgml : 20220929 20220929160516 ACCESSION NUMBER: 0000899243-22-032236 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220927 FILED AS OF DATE: 20220929 DATE AS OF CHANGE: 20220929 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Michaelson Jennifer CENTRAL INDEX KEY: 0001838061 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39856 FILM NUMBER: 221280553 MAIL ADDRESS: STREET 1: C/O CULLINAN MANAGEMENT, INC. STREET 2: ONE MAIN STREET SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cullinan Oncology, Inc. CENTRAL INDEX KEY: 0001789972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813867811 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-410-4650 MAIL ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Management, Inc. DATE OF NAME CHANGE: 20210107 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Oncology, LLC DATE OF NAME CHANGE: 20191001 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-09-27 0 0001789972 Cullinan Oncology, Inc. CGEM 0001838061 Michaelson Jennifer C/O CULLINAN ONCOLOGY, INC. ONE MAIN STREET, SUITE 520 CAMBRIDGE MA 02142 0 1 0 0 See Remarks Common Stock 2022-09-27 4 M 0 4000 4.30 A 57031 D Common Stock 2022-09-27 4 S 0 4000 12.40 D 53031 D Stock Option (Right to Buy) 4.30 2022-09-27 4 M 0 4000 0.00 D 2030-10-28 Common Stock 4000 204593 D Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021, as amended on June 24, 2022. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.30 to $12.56. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Chief Development Officer, Biologics /s/ Jeffrey Trigilio, Attorney-in-Fact 2022-09-29